Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling

Area of Science:

• Oncology
• Mathematical Biology
• Pharmacology

Background:

• Acquired chemotherapy resistance significantly reduces treatment efficacy.
• Shifting cancer treatment from eradication to chronic disease management is being explored.
• Metronomic chemotherapy (low, continuous doses) targets endothelial cells and combats drug resistance.

Purpose of the Study:

• To investigate the hypothesis that lower chemotherapy doses are beneficial for cancer patients.
• To analyze the effects of metronomic therapy using mathematical modeling.
• To compare metronomic therapy with traditional maximum tolerated dose approaches.

Main Methods:

• Utilized mathematical modeling and optimal control techniques.
• Adapted a tumor growth model incorporating angiogenic signaling (Hahnfeldt et al.).
• Simulated heterogeneous tumors treated with combined anti-angiogenic agents and chemotherapy.

Main Results:

• Mathematical models indicate that intermediate drug doses lead to the longest patient survival times.
• Optimal short-term chemotherapy scheduling involves low-dose drug application for disease maintenance.
• The study supports the concept of treating cancer as a chronic condition.

Conclusions:

• Metronomic therapy presents an attractive alternative to conventional maximum tolerated dose chemotherapy.
• Further investigation in experimental settings and clinical trials is warranted for metronomic therapy.
• Mathematical modeling provides valuable insights into optimizing chemotherapy regimens for improved patient outcomes.